Assessing the Trillium takeout
Prospects for other biotech players
Biotech got a jolt of life after Pfizer announced the $2.26B acquisition of Trillium (TRIL), at a 204% premium to market close on Friday. The premium seems inflated due to the recent carnage seen in biotech, especially small cap bios. If the same acquisition would have happened 6-months ago, back in February, when Trillium had similar fundamentals, Pfiz…